Rotterdam engineering company TBI is building the new reactor for the production of medical isotopes in Petten. The company will be doing this in collaboration with Argentinian state-owned company Invap, which is in charge of the consortium that has been formed for the assignment.
This is shown through a press release on Invap's website and through messages from the building trade magazine Cobouw. According to Cobouw the installation, which will cost hundreds of millions of euros and for which the Department of Economics and the province of North-Holland have set up a loan for €80 million, will be completed by 2025. The first, preparatory phase is budgeted at a maximum of €40 million.
Invap says they were assigned the construction in 2009, but the Dutch government postponed the order due to the economic crisis. The companies that competed with Invap in 2015, in retrieving the assignment, came from France (TechnicAtom) and South Korea (Kaeri).
According to Cobouw, TBI daughters Croonwolter&dros and Mobilis are involved in the installation. The new reactor, Pallas, is set to replace the old, so-called high flux reactor in Petten, which was built almost 60 years ago.
The high flux reactor is property of the European Commission. The operator is Nuclear Research and Consultancy Group (NRG), a Dutch company that was born out of a collaboration between the Energy Research Center Netherlands and the former inspection institute for the Dutch electricity sector, Kema.